BASIS FOR ISSUE PRICE

The Price Band and Issue Price will be determined by our Company in consultation with the Book running Lead Manager on the basis of assessment of market demand for the Equity Shares issued through the Book Building Process and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹10 each and the Issue Price is [●] times the Floor Price and [●] times the Cap Price, and Floor Price is 9.3 times the face value and the Cap Price is 9.8 times the face value. Investors should read the following basis with the sections titled "***Risk Factors***", "***Restated Financial Information***" and the chapter titled "***Our Business***" on page 33, 242 and 175 respectively, of this Red Herring Prospectus to get a more informed view before making any investment decisions. The trading price of the Equity Shares of our Company could decline due to these risk factors and you may lose all or part of your investments.

Qualitative Factors

Some of the qualitative factors and our strengths which form the basis for the Issue Price are:

1. Integrated and flexible manufacturing operations for sustainable formulations enabling customized supply
2. Strong understanding of applied chemistries for diverse end-use industries;
3. Established long-standing relationships with customers across end-use industries;
4. Research and development (R&D) capabilities for development of innovative performance chemistries;
5. Established sales and distribution network;
6. Experienced Promoters with strong management team having domain knowledge.

For more details on qualitative factors, please refer *"**Our Business**"* on page 175 of this Red Herring Prospectus.

Quantitative Factors

The information presented in this section is derived from our Restated Financial Statements. For more details on financial information, investors please refer the chapter titled "***Restated Financial Information***" on page 242 of this Red Herring Prospectus. Investors should evaluate our Company taking into consideration its earnings and based on its growth strategy. Some of the quantitative factors which may form the basis for computing the price are as follows:

1. **Basic and Diluted Earnings per Equity Share ("EPS"), adjusted for changes in capital:**

Financial period	Basic & Diluted EPS (in ₹)*	Weight
Fiscal 2025	6.64	3
Fiscal 2024	1.90	2
Fiscal 2023	2.03	1
Weighted Average	**4.29**	**-**
For the six months period ended September 30,2025	4.52**	

** The EPS computed above is derived after considering the bonus share issued by the Company in ratio of 3:4 (3 shares for every 4 shares held) on July 05, 2025.*
***Not annualised*

Notes:
1) *Earning per Share are in accordance with Accounting Standard 20 – Earnings per Share, as amended*
2) *Basic Earnings per Equity Share (₹): Profit for the year/period, as, restated divided by weighted overage number of equity shares outstanding during the period/year*
3) *Diluted Earnings per Equity Share (₹): Profit for the year/period, as, restated divided by weighted average number of diluted equity shares outstanding during the period/year*
4) *Weighted Average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. (EPS x Weight) for each year/total of weights*
5) *The figures disclosed above are based on the Restated Financial Statements.*

2. **Price Earning (P/E) Ratio in relation to Price Band of ₹ 93 to ₹ 98 per Equity Share:**

Particulars	P/E at the Floor Price (number of times)	P/E at the Cap Price (number of times)
Based on basic and diluted EPS for Fiscal 2025	14.01	14.76

3. **Industry Peer Group P/E Ratio**

Based on the peer group information (excluding our Company) given below in this section:

Particulars	P/E Ratio (No. of times)
Highest	26.00
Lowest	8.83
Average	**17.42**

Note:

(1) Please refer point 8 below for calculation of P/E ratio of industry peer group.

(2) The industry high and low has been considered from the industry peers set provided later in this chapter.

*(3) The average has been calculated as the arithmetic average of P/E of all industry peers set disclosed in this section. For further details, see "**Basis for Issue Price–Comparison of accounting ratios with Industry Peers**" on page 127 of this Red Herring Prospectus.*

4. **Return on Net Worth ("RoNW"):**

Financial period	RoNW (%)	Weight
Fiscal 2025	48.82%	3
Fiscal 2024	17.97%	2
Fiscal 2023	18.07%	1
Weighted Average	**33.41%**	
For the six months period ended September 30, 2025	21.10%*	

**Not annualised*

Notes:

(1) Weighted average = Aggregate of year-wise weighted Return on Net Worth divided by the aggregate of weights i.e. (Return on Net Worth x Weight) for each year/Total of weights.

(2) Return on Net Worth (%) = Restated profit for the year/period divided by average net worth, where average net worth is calculated by dividing sum of closing net worth of the current fiscal year/period and closing net worth of the previous fiscal year by 2. Net Worth of FY 22 is taken from restated consolidated financial statements.

(3) Net worth = Equity Share capital plus Reserves and Surplus.

5. **Net Asset Value per Equity Share(1):**

Particulars	NAV (₹)(2)
As at September 30, 2025	25.72
As at March 31, 2025	16.91
After the Issue#	
- At Floor Price	43.76
- At Cap Price	45.10
Issue Price	[●]

 # to be included upon determination of floor price, Cap Price and Issue Price

Note:

(1) Net Asset Value per Equity Share = Net worth derived from Restated Financial Statements as at the end of the year/period divided by number of equities shares outstanding as at the end of the period /year as per Restated Financial Statements.

(2) The 'Net worth' defined above is in accordance with 2(1)(hh) of the SEBI ICDR Regulations, i.e. "net worth" means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

(3) NAV computed above is derived after considering the bonus share issued by the Company in ratio of 3:4 (3 shares for every 4 shares held) on July 05, 2025.

6. **Key Financial and Operational Performance Indicators**

The table below sets forth the details of the key financial and operational performance indicators ("**KPIs**") that our Company considers have a bearing for arriving at the basis for Issue Price. These KPIs have been used historically by our Company to understand and analyse business performance, which in result, help us in analysing the growth of various vertical segments. The Bidders can refer to the below-mentioned KPIs to make an assessment of our Company's performance in various business verticals and make an informed decision.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated November 21, 2025 and the Audit Committee has confirmed that the KPIs pertaining to our Company that have been disclosed to investors at any point of time during the three years period prior to the date of this Red Herring Prospectus have been disclosed in this section and have been subject to verification and certification by M/s Patel Mehta & Associates, Chartered Accountants, bearing firm registration number 107773W, pursuant to certificate dated November 21, 2025, which has been included as part of the "***Material Contracts and Documents for Inspection***" on page 430 of this Red Herring Prospectus.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Issue Section, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations, 2018.

For details of our key operating, financial and other operating metrics disclosed elsewhere in this Red Herring Prospectus, see "***Our Business***" on page 175 and "***Management's Discussion and Analysis of Financial Condition and Result of Operations***" on page 289 of this Red Herring Prospectus**.**

Set forth below are KPIs which have been used historically by our Company to understand and analyse the business performance, which in result, help us in analyzing the growth of various verticals of the Company that have a bearing for arriving at the Basis for the Issue Price:

(₹ in lakhs except percentages and ratios)

Sr. No.	Particulars	For the six months period ended September 30,2025	Fiscal 2025	Fiscal 2024	Fiscal 2023
1	Revenue from Operations (₹ in lakhs)	4,583.16	8,417.27	6,114.63	4,818.84
2	Total income (₹ in lakhs) (1)	4,718.16	8,615.35	6,200.75	4,879.03
3	EBITDA (₹ in lakhs) (2)	859.23	1,311.29	599.01	422.84
4	EBITDA Margin (%)(3)	18.75%	15.58%	9.80%	8.77%
5	Profit After Tax ("PAT") (₹ in lakhs)	548.38	775.07	180.13	107.29
6	PAT Margin (%)(4)	11.62%	9.00%	2.91%	2.20%
7	Cash Profit After Tax (₹ in lakhs)(5)	611.55	907.81	302.09	228.98
8	Net Worth(6)	3,223.66	1,975.27	1,200.21	805.14
9	Current Ratio (times) (7)	1.45	1.21	1.17	1.09
10	Debt-Equity Ratio (times) (8)	1.20	1.80	2.78	3.26
11	Return on Equity (%)(9)	21.10%*	48.82%	17.97%	18.07%
12	Return on Capital Employed(%)(10)	22.84%*	41.67%	21.46%	17.46%

As certified by statutory auditors Patel Mehta & Associates, Chartered Accountants vide their certificate dated November 21, 2025

**Not annualised*

Notes:

1. *Total income has been calculated as sum of Revenue from operations and other income.*
2. *EBITDA has been calculated as a sum of profit before tax, finance costs and depreciation and amortization less other income*
3. *EBITDA Margins is calculated as EBITDA divided by Revenue from Operations.*
4. *PAT Margins (%) is calculated as Profit After Tax carried to balance sheet divided by Total Income.*
5. *Cash Profit After Tax is calculated as a sum of Profit After Tax to balance sheet and Depreciation and Amortisation as per Restated Financial Statements.*
6. *Net worth is calculated as Equity Share Capital plus Reserve and Surplus.*
7. *Current Ratio is calculated as Total Current Assets divided by Total Current Liabilities.*
8. *Debt-Equity Ratio is calculated as Total Debt divided by Net-Worth as per Restated Financial Statements. Total Debt is calculated as a sum of Long-Term Borrowings and Short-Term Borrowings (including current maturity of long-term borrowings).*
9. *Return on Equity is calculated as Restated profit after tax After Tax carried to balance sheet for the year/period divided by average net worth, where average net worth is calculated by dividing sum of closing net worth of the current fiscal year and closing net worth of the previous fiscal year by 2. Net worth of FY 2022 is taken from restated consolidated financial statements for Neochem Bio Solutions Limited. Net worth of FY 2022 is taken from audited consolidated financial statements for Peer Companies.*
10. *Return on Capital Employed is calculated as Earnings Before Interest and Tax divided by Average Capital Employed. Average Capital Employed is calculated by dividing closing capital employed of the current fiscal year/period and closing capital employed of the previous fiscal year by 2. Capital employed is calculated as total assets less total current liabilities. Capital Employed of FY 2022 is taken from restated consolidated financial statements of FY 22 for Neochem Bio Solutions Limited. Capital Employed of FY 2022 is taken from audited consolidated financial statements for Peer Companies.*

KPIs disclosed above has been approved by the Audit Committee of the Company in their meeting held on dated November 21, 2025.

7. Description on the historic use of the KPIs by our Company to analyse, track or monitor the operational and/or financial performance of our Company

The KPIs disclosed below have been used historically by the Company to understand and analyze the business performance, which in result, help it in analyzing the growth of various verticals, and other relevant and material KPIs of the business of the Company that have a bearing for arriving at the Basis for Issue Price have been disclosed below. The KPIs set forth above have been approved by the Audit Committee pursuant to its resolution dated November 21, 2025.

The list of the KPIs along with brief explanation of the relevance of the KPIs for the business operations of the Company are set forth below:

Sr No.	KPIs	Explanation
1.	Revenue from Operations	Revenue from operation provided information regarding growth of our core business operations over the period
2.	Total income	Total income provides information regarding income earned by the Company during the period and provides key insight about the financial performance of the Company over the period of time
3.	Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA)	EBITDA provides information regarding operational profitability and the financial performance of the business.
4.	EBITDA Margins	EBITDA margin provides the financial benchmarking against peers as well as to compare against the historical performance of the business.
5.	Profit after Tax (PAT)	PAT provides information regarding the overall Profitability of the business.
6.	PAT Margins (%)	PAT margin is an indicator of the overall profitability of the business and provides the financial benchmarking against peer as well as to compare against the historical performance of the business.
7.	Cash Profit after Tax	Cash Profit after Tax is an indicator which denotes profit generated from the business operations during the period before adjusting the non-cash items
8.	Current Ratio	Current ratio is an indicator of short-term solvency i.e., company's ability to pay short-term obligations or those due within one year.

Sr No.	KPIs	Explanation
9.	Net Worth	Net Worth is an indicator of total net worth after deducting the aggregate value of the accumulated losses, each as applicable for the company on a restated basis.
10.	Debt-Equity Ratio	Debt Equity Ratio is an indicator of overall leverage of the company
11.	Return on Equity (%)	RoE provides how efficiently the Company generates profits from average shareholders' funds.
12.	Return on Capital Employed (%)	RoCE provides how efficiently the Company generates earnings from the capital employed in the business.

8. Comparison of accounting ratios with Industry Peers

Our Company believe following are its peer group which has been determined on the basis of listed public companies comparable in the similar line of segments in which our Company operates and whose business segment in part or full may be comparable with that of our business, however, the same may not be exactly comparable in size or business portfolio on a whole with that of our business.

Following is the comparison with peer companies listed in India:

Name of the Company	Consolidated / Standalone	Face value (₹ per share)	Closing Price on October 31, 2025 (₹ per share)	Revenue from Operations for six months period ended September 30, 2025 (₹ in Lakhs)*	EPS (Basic and Diluted) (₹)**	NAV (₹ per share)	P/E Ratio on Closing Price	RoNW (%)*#
Neochem Bio Solutions Limited	Consolidated	10	N.A.	4,583.16	4.52	25.72	N.A.	21.10%
Listed Industry Peers								
Rossari Biotech Limited	Consolidated	2	640.95	1,12,982.30	24.66	226.05	26.00	5.78%
Indian Emulsifiers Limited	Consolidated	10	100.70	7,698.04	11.40	75.54	8.83	11.78%

**Financial information for our Company is derived from the Restated Financial Statements as at and for the six months period ended September 30,2025.*
***EPS has been computed as on March 31,2025.*
#Not annualised
***Source**: All the financial information for listed industry peers mentioned above is sourced from the financial statements of the relevant companies for the six months period ended September 30,2025, as available on the websites of the Stock Exchange.*

Notes for peer group:
1. *P/E Ratio has been computed based on the closing market price of equity shares on NSE on October 31, 2025 divided by the Basic EPS as at March 31, 2025.*
2. *Return on Net Worth (%) = Profit for the year/period divided by average net worth of the Company.*
3. *Net asset value per equity share means Net Worth divided by outstanding number of equity shares as at the end of the financial year/period. Net worth of the Company means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.*

9. Comparison of KPIs with listed industry peers

(₹ in lakhs, except ratios and per share data)

Particulars	Neochem Bio solutions Limited				Rossari Biotech Limited				Indian Emulsifiers Limited			
	September 30,2025	FY25	FY24	FY23	September 30, 2025	FY25	FY24	FY23	September 30, 2025	FY25	FY24	FY23
Revenue from Operations	4,583.16	8,417.27	6,114.63	4,818.84	1,12,982.30	2,08,029.40	1,83,055.80	1,65,588.10	7,698.04	10,122.62	6,667.60	4,117.97
Total Income[(a)]	4,718.16	8,615.35	6,200.75	4,879.03	1,13,262.70	2,08,430.30	1,83,800.40	1,66,136.50	7,722.74	10,265.51	6,671.36	4,118.35
EBITDA[(b)]	859.23	1,311.29	599.01	422.84	14,076.80	26,606.00	24,993.10	22,398.10	1,509.27	1,961.87	1,478.98	786.19
EBITDA Margin[(c)]	18.75%	15.58%	9.80%	8.77%	12.43%	12.76%	13.60%	13.48%	19.54%	19.11%	22.17%	19.09%
PAT for the Year	548.38	775.07	180.13	107.29	7,047.20	13,637.80	13,068.90	10,725.70	1,026.94	1,329.90	882.37	389.44
PAT Margin[(d)]	11.62%	9.00%	2.91%	2.20%	6.22%	6.54%	7.11%	6.46%	13.30%	12.96%	13.23%	9.46%
Cash Profit After Tax[(e)]	611.55	907.81	302.09	228.98	10,645.40	20,345.10	19,107.90	17,018.80	1,139.79	1,552.42	1,051.21	507.65
Current Ratio[(f)]	1.45	1.21	1.17	1.09	1.73	1.94	1.99	2.07	2.69	2.67	1.95	2.04
Net Worth[(g)]	3,223.66	1,975.27	1,200.21	805.14	1,25,149.90	1,18,544.90	1,04,772.80	91,516.60	9,230.41	8,203.47	2,843.75	1,204.35
Debt-Equity Ratio[(h)]	1.20	1.80	2.78	3.26	0.27	0.17	0.11	0.09	0.37	0.46	1.17	2.01
ROE[(i)]	21.10*%	48.82%	17.97%	18.07%	5.78%*	12.21%	13.32%	12.47%	11.78%*	24.08%	43.59%	38.57%
ROCE[(j)]	22.84*%	41.67%	21.46%	17.46%	7.68%*	16.19%	18.19%	16.81%	14.61%*	28.79%	40.06%	33.67%

Sources:

All the financial information for listed industry peers mentioned above is sourced from the Annual Reports of the aforesaid companies for the respective years

Notes:

a) Total income has been calculated as sum of Revenue from operations and other income.

b) EBITDA has been calculated as a sum of profit before tax, finance costs and depreciation and amortization less other income.

c) EBITDA Margins is calculated as EBITDA divided by revenue from operations.

d) PAT Margins (%) is calculated as Profit After Tax carried to balance sheet divided by Total Income.

e) Cash Profit After Tax is calculated as a sum of Profit After Tax to balance sheet and depreciation and amortisation as per Restated Financial Statements.

f) Current Ratio is calculated as Total Current Assets divided by Total Current Liabilities.

g) Net worth is calculated as Equity Share Capital plus Reserve and Surplus.

h) Debt-Equity Ratio is calculated as Total Debt divided by Net-Worth as per Restated Financial Statements of Neochem Bio Solutions Limited. Debt-Equity Ratio is calculated as Total Debt divided by Net-Worth as per audited consolidated financial statements for Peer Companies. Total Debt is calculated as a sum of Long-Term Borrowings and Short-Term Borrowings (including current maturity of long-term borrowings).

i) Return on Equity is calculated as Restated profit after tax After Tax carried to balance sheet for the year/period divided by average net worth, where average net worth is calculated by dividing sum of closing net worth of the current fiscal year/period and closing net worth of the previous fiscal year by 2. Net worth of FY 2022 is taken from restated consolidated financial statements for Neochem Bio Solutions Limited. Net worth of FY 2022 is taken from audited consolidated financial statements for Peer Companies.

j) Return on Capital Employed is calculated as Earnings Before Interest and Tax divided by Average Capital Employed. Average Capital Employed is calculated by dividing sum of closing capital employed of the current fiscal year/period and closing capital employed of the previous fiscal year by 2. Capital employed is calculated as total assets less total current liabilities. Capital Employed of FY 2022 is taken from restated consolidated financial statements of FY 22 for Neochem Bio Solutions Limited. Capital Employed of FY 2022 is taken from audited consolidated financial statements for Peer Companies.

10. Comparison of Key Performance Indicators over time shall be explained based on additions or dispositions to our business

Our Company has not made any additions or dispositions to its business during the six months period ended September 30, 2025 and Financial year ended March 31, 2025, March 31, 2024 and March 31, 2023. For further details see "***History and Certain Corporate Matters***" on page 215 of this Red Herring Prospectus.

11. Weighted Average Cost of Acquisition, Floor Price and Cap Price

a. Price per share of the Company (as adjusted for corporate actions, including split, bonus issuances) based on primary issuances of Equity Shares or convertible securities (excluding Equity Shares issued under Employee Stock Option Scheme and issuance of Equity Shares pursuant to a bonus issue) during the 18 months preceding the date of this Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Issuances")

The details of the Equity Shares or convertible securities, excluding issuance of bonus shares, during the 18 months preceding the date of this Red Herring Prospectus, where such issuance is equal to or more that 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre- Issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("**Primary Issuance**") are as follows:

Date of allotment	No. of shares transacted*	Face Value (in ₹)	Issue price per share*	Nature of allotment	Nature of consideration	Total consideration (in ₹)
July 5, 2025	4,86,116	10	144	Private Placement	Cash	7,00,00,704
Total	**4,86,116**					**7,00,00,704**
Weighted Average Cost of Acquisition [Total Consideration/Total Number of Shares Transacted]						**82.29^**

^weighted average cost is calculated after giving effect of bonus Equity Shares issued in the ratio of 3:4 on July 05, 2025

Except as stated above, it is confirmed that there are no primary/new issue of shares, equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated on the pre-issue capital on the date of allotment) in the 18 months prior to the date of this Red Herring Prospectus.

b. Price per share of the Company (as adjusted for corporate actions, including bonus issuances) based on secondary sale or acquisition of equity shares or convertible securities (excluding gifts) involving the Promoters, members of the Promoter Group, the Selling Shareholder or other Shareholders of the Company with rights to nominate directors during the 18 months preceding the date of filing of the DRHP/ RHP, where the acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-Issue capital before such transaction/s, and excluding ESOPs granted but not vested) in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions")

There has been no secondary sale/ acquisitions of Equity Shares or any convertible securities ("Security(ies)"), where the Promoters, members of the Promoter Group, Selling Shareholders, or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre- Issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

c. Price per share based on the last five primary or secondary transactions

Since there are transactions to report to under (a) and (b) above, therefore, information based on last 5 primary or secondary transactions (secondary transactions where Promoter / Promoter Group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in the Board of the Company, are a party to the transaction) not older than 3 years prior to the date of Red Herring Prospectus irrespective of the size of transactions is not required to disclosed.

d. Weighted average cost of acquisition, Floor Price and Cap Price:

Type of transaction	WACA (in ₹)	Floor Price (₹93)*	Cap Price (₹98)*
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of filing of this Red Herring Prospectus, where such issuance is equal to or more than nine per cent of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	82.29^	1.13	1.19
Weighted average cost of acquisition for last 18 months for secondary sale / acquisition of shares equity / convertible securities), where promoter / promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of this Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	NIL	NIL	NIL
Since there are transactions to report in (A) or (B) above, therefore, information based on last 5 primary or secondary transactions (secondary transactions where promoter/promoter group entities or selling shareholder or shareholder(s) having right to nominate director(s) in the Board of the Company, are a party to the transaction) not older than 3 years prior to the date of this Red Herring Prospectus irrespective of the size of transactions is not required to disclosed			
Last 5 primary transactions	N.A.	N.A.	N.A.
Last 5 secondary transactions	N.A.	N.A.	N.A.

** To be updated at Prospectus stage after finalization of price band.*
^weighted average cost is calculated after giving effect of Bonus issue in the ratio of 3:4 on shares transaction mentioned prior to July 5, 2025

12. Justification for Basis of Issue price

The following provides an explanation for the Issue Price/Cap Price being [●] times of weighted average cost of acquisition of Equity Shares that were issued by our Company or acquired or sold by our Promoter, the Promoter Group or other shareholders with rights to nominate directors by way of primary and secondary transactions as disclosed in paragraph above, in the last 18 months preceding the date of this Red Herring Prospectus compared to our Company's KPIs and financial ratios for the September 30,2025, Fiscal 2025, 2024 and 2023.

1. We are a specialty performance chemical company with a legacy of over four decades, engaged in the business of manufacturing specialty performance chemicals with a diverse portfolio of over 350 customized formulations across four primary product segments *viz.,*(i) Polymers, (ii) Surfactants, (iii) Silicones, and (iv) Esters & biobased sustainable solutions. Our products are essential and used in industries such as textile & garment washing, home & personal care (HPC), institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction, rubber and dyes and pigments.

2. We operate an integrated manufacturing facility with an installed capacity of 22,000MTPA at Moraiya, Ahmedabad that enables us to produce key intermediates in-house and develop proprietary formulations for diverse customer requirements. Our manufacturing facility is equipped to handle multiple chemistries such as polymer based acrylic dispersants formulation, bio-based esters and silicone based formulations and products based on surfactant chemistry which supports intermediate manufacturing and formulation processes.

3. With over four decades of operational experience and technically qualified team, we have developed strong application and process knowledge across a wide range of industries such as textiles and garment washing, home and personal care, industrial and institutional cleaning, construction chemicals, paint and coatings, water treatment, paper and pulp, rubber, and dyes and pigment. Our understanding of customer-specific product requirements, combined with our formulation capabilities, enables us to deliver specialty performance chemicals that meet functional, regulatory and quality standards across diverse industrial applications.

4. Our understanding of chemical behaviour across diverse industrial processes enabled us to establish and strengthen long-standing relationships with a wide range of customers. Our sales are complemented by the distribution network of more than 50 distributors. In domestic market, we have catered 228, 227, 254 and 188 customers during six months period ended September 30, 2025, Fiscals 2025, 2024 and 2023, respectively. In the international market, we have catered to more than 10, 16, 17 and 14 customers during six months period ended September 30, 2025, Fiscal 2025, 2024 and 2023, respectively.

5. Our in-house R&D and product application development laboratory located at our manufacturing facility in Moraiya, Ahmedabad, is equipped with advanced testing and formulation infrastructure and operated by a team of qualified professionals including support staff. Our commitment to sustainable product innovation is validated by certifications such as ZDHC Level 3, and Global Organic Textile Standard (GOTS 7.0) and ISO 14001 for environmental management. These accreditations demonstrate our ability as a supplier to meet international standards for environmental and chemical safety.

6. We have an experienced management team led by our Promoter and Managing Director, Swapnil Rameshbhai Makati, who has over 20 years of experience in the field of manufacturing and trading of specialty performance chemicals industry. Our Chairman and Non-Executive Director, Dinesh Chopra, over 25 years of industry experience. Our Director and one of our Promoters, Hemangini Swapnil Dathia, has over sixteen years of experience in the specialty chemical industry. Our management team has achieved consistent business growth and financial performance which led to growth of our total revenue from operations from ₹4,818.84 lakhs in Fiscal 2023 to ₹8,417.27 lakhs in Fiscal 2025 representing CAGR of 32.16%.

The Price Band of ₹ 93 – ₹ 98 has been determined by our Company, in consultation with the BRLM, on the basis of the demand from investors for the Equity Shares through the Book Building process. Investors should read the abovementioned information along with "***Risk Factors***", "***Our Business***" and "***Restated Financial Information***" on pages 33, 175 and 242 respectively of this Red Herring Prospectus, to have a more informed view.